JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
6276
BBVA Argentina
BBAR
$2.54B
| $4.88K | ﹤0.01% |
256
| – | – |
2020 Q3
17 quarters
|
|
|
CCD
6277
Calamos Dynamic Convertible & Income Fund
CCD
$643M
| $4.86K | ﹤0.01% |
+200
| New | +$4.91K |
2024 Q4
0 quarters
|
|
6278
WisdomTree Trust WisdomTree Emerging Markets Quality Dividend Growth Fund
DGRE
$150M
| $4.85K | ﹤0.01% |
193
-4
| -2% | -$105 |
2023 Q1
7 quarters
|
|
6279
ProShares Short High Yield
SJB
$52.7M
| $4.84K | ﹤0.01% |
300
-100
| -25% | -$1.63K |
2023 Q4
4 quarters
|
|
|
ASBPW
6280
Aspire-Lakewood Holdings, Inc. Warrant
ASBPW
| – | – |
0
| – | – |
2023 Q4
4 quarters
|
|
|
AVK
6281
Advent Convertible and Income Fund
AVK
$500M
| $4.71K | ﹤0.01% |
400
| – | – |
2022 Q4
8 quarters
|
|
|
WHWK
6282
Whitehawk Therapeutics
WHWK
$214M
| $4.66K | ﹤0.01% |
1,478
-2,759
| -65% | -$6.25K |
2022 Q2
10 quarters
|
|
6283
FT Vest US Equity Moderate Buffer ETF August
GAUG
$418M
| $4.66K | ﹤0.01% |
132
-778
| -85% | -$27.4K |
2024 Q2
2 quarters
|
|
6284
Gossamer Bio
GOSS
$66.9M
| $4.65K | ﹤0.01% |
64
+55
| +611% | +$3.77K |
2024 Q1
3 quarters
|
|
6285
ETRACS UBS Bloomberg Constant Maturity Commodity Index (CMCI) Total Return ETN Series B due Apr 5 2038
UCIB
$35.7M
| $4.64K | ﹤0.01% |
180
| – | – |
2023 Q3
5 quarters
|
|
6286
FT Vest US Equity Buffer ETF June
FJUN
$1.42B
| $4.62K | ﹤0.01% |
90
-11,841
| -99% | -$608K |
2022 Q4
8 quarters
|
|
6287
Gabelli Dividend & Income Trust
GDV
$2.44B
| $4.59K | ﹤0.01% |
190
| – | – |
2022 Q3
9 quarters
|
|
6288
AllianzIM U.S. Equity Buffer10 Sep ETF
SEPT
$38.4M
| $4.53K | ﹤0.01% |
148
-2,885
| -95% | -$88.2K |
2024 Q2
2 quarters
|
|
6289
Invesco Value Municipal Income Trust
IIM
$504M
| $4.45K | ﹤0.01% |
374
| – | – |
2022 Q4
8 quarters
|
|
6290
iShares iBonds Dec 2027 Term Treasury ETF
IBTH
$2.39B
| $4.44K | ﹤0.01% |
+200
| New | +$4.46K |
2024 Q4
0 quarters
|
|
6291
State Street SPDR S&P Emerging Markets Dividend ETF
EDIV
$1.16B
| $4.41K | ﹤0.01% |
125
-4,000
| -97% | -$145K |
2024 Q3
1 quarter
|
|
6292
Immuneering
IMRX
$261M
| $4.34K | ﹤0.01% |
1,974
-450
| -19% | -$933 |
2021 Q3
13 quarters
|
|
6293
Invesco DB Energy Fund
DBE
$118M
| $4.19K | ﹤0.01% |
226
-790
| -78% | -$15.1K |
2022 Q1
11 quarters
|
|
6294
AllianzIM U.S. Equity Buffer10 Jan ETF
JANT
$62.2M
| $4.18K | ﹤0.01% |
116
-1,674
| -94% | -$59.6K |
2024 Q3
1 quarter
|
|
6295
CEL-SCI Corp
CVM
$36.8M
| $4.18K | ﹤0.01% |
348
+339
| +3,767% | +$7.82K |
2019 Q2
22 quarters
|
|
6296
Innovator US Equity Power Buffer ETF July
PJUL
$1.3B
| $4.18K | ﹤0.01% |
101
-3,528
| -97% | -$145K |
2024 Q1
3 quarters
|
|
6297
Emergent Biosolutions
EBS
$327M
| $4.15K | ﹤0.01% |
434
-209
| -33% | -$1.92K |
2014 Q1
43 quarters
|
|
6298
Royce Value Trust
RVT
$2.12B
| $4.15K | ﹤0.01% |
262
+23
| +10% | +$367 |
2023 Q3
5 quarters
|
|
|
AIO
6299
Virtus Artificial Intelligence & Technology Opportunities Fund
AIO
$866M
| $4.14K | ﹤0.01% |
168
-66
| -28% | -$1.54K |
2024 Q1
3 quarters
|
|
6300
China Automotive Systems
CAAS
$145M
| $4.14K | ﹤0.01% |
1,009
-882
| -47% | -$3.85K |
2023 Q4
4 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.